Hantz Financial Services Inc. lifted its holdings in Humana Inc. (NYSE:HUM – Free Report) by 555.4% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 10,552 shares of the insurance provider’s stock after acquiring an additional 8,942 shares during the quarter. Hantz Financial Services Inc.’s holdings in Humana were worth $4,026,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Vista Investment Partners LLC purchased a new stake in Humana in the 3rd quarter worth approximately $3,254,000. Manning & Napier Advisors LLC bought a new stake in shares of Humana during the 2nd quarter worth about $1,412,000. The Manufacturers Life Insurance Company boosted its position in Humana by 10.5% during the second quarter. The Manufacturers Life Insurance Company now owns 70,185 shares of the insurance provider’s stock worth $27,879,000 after purchasing an additional 6,690 shares during the period. Pzena Investment Management LLC acquired a new position in Humana during the second quarter valued at approximately $1,749,014,000. Finally, Ameritas Advisory Services LLC acquired a new position in Humana during the second quarter valued at approximately $1,709,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.
Insider Buying and Selling at Humana
In other news, insider Joseph Ventura sold 5,495 shares of Humana stock in a transaction on Monday, November 9th. The shares were sold at an average price of $433.85, for a total transaction of $2,384,005.75. Following the transaction, the insider directly owned 21,910 shares of the company’s stock, valued at $9,505,653.50. This trade represents a 20.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.20% of the company’s stock.
Analysts Set New Price Targets
A number of analysts have recently weighed in on the stock. Oppenheimer boosted their price objective on shares of Humana from $475.00 to $525.00 and gave the stock an “outperform” rating in a research note on Monday, October 12th. KeyCorp downgraded shares of Humana from an “overweight” rating to a “sector weight” rating in a report on Monday. Wells Fargo & Company lowered shares of Humana from an “overweight” rating to an “underweight” rating in a research note on Monday. Barclays lifted their target price on shares of Humana from $582.00 to $587.00 and gave the stock an “overweight” rating in a report on Monday, November 9th. Finally, Morgan Stanley raised shares of Humana from an “underweight” rating to an “overweight” rating in a research report on Friday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $482.96.
Read Our Latest Research Report on Humana
Humana Stock Performance
HUM opened at $461.86 on Tuesday. The company has a quick ratio of 1.74, a current ratio of 1.65 and a debt-to-equity ratio of 0.61. The stock’s 50 day moving average price is $409.75 and its two-hundred day moving average price is $318.25. The firm has a market capitalization of $55.47 billion, a P/E ratio of 33.46, a price-to-earnings-growth ratio of 2.11 and a beta of 0.65. Humana Inc. has a 12-month low of $163.11 and a 12-month high of $462.87.
Humana (NYSE:HUM – Get Free Report) last posted its quarterly earnings data on Friday, November 6th. The insurance provider reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.30. Humana had a return on equity of 8.50% and a net margin of 0.81%. The company had revenue of $41.16 billion during the quarter, compared to analysts’ expectations of $40.87 billion. During the same period in the prior year, the business earned $3.24 earnings per share. Humana’s revenue for the quarter was up 26.1% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.500- EPS. On average, equities analysts forecast that Humana Inc. will post 9.66 earnings per share for the current year.
Humana Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, January 29th. Stockholders of record on Thursday, December 24th will be paid a $0.8850 dividend. The ex-dividend date is Thursday, December 24th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.8%. Humana’s dividend payout ratio (DPR) is 34.44%.
About Humana
Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.
Featured Articles
- Five stocks we like better than Humana
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Free Report).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
